Sign in
Taking people in United StatesNo phase

Searching for genes behind Charcot-Marie-Tooth disease and its symptom differences

Looks for genes causing or changing symptoms in people with Charcot-Marie-Tooth disease.

Key facts

Who runs it
University of Iowa
Where
Ann Arbor, Aurora, Baltimore, Boston, Chapel Hill, Columbus, Hartford, Houston, Iowa City, Los Angeles, Maple Grove, Memphis, Miami, Palo Alto, Philadelphia, Rochester, and Seattle, United StatesSee the 18 sitesAlso in 5 other countries, 6 sites
Trial code
Registry title
Genetics of Charcot Marie Tooth (CMT) - Modifiers of CMT1A, New Causes of CMT2
Status
Recruiting
People taking part
1,050 people, planned
Started
May 2010
Expected to end
Dec 2030
Type of study
Observational, 2 groups
Record updated
27 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for people with Charcot Marie Tooth disease (CMT), a nerve disease that runs in families, and their family members. It studies genes that cause CMT or change its symptoms.

Sex
All sexes can join.
Disease stage
Patients must have nerve damage (neuropathy) shown on nerve tests, or an inherited neuropathy diagnosed by a doctor. Family members can join as controls, with or without signs of neuropathy.
Biomarker or test result
For the CMT1A study: a documented PMP22 duplication, or a close relative with one and a clear family link. For the new-gene (exome) study: no genetically confirmed form of CMT.

Main reasons for not taking part

  • Nerve damage known to come from a non-genetic cause, such as chemotherapy (Vincristine, Taxol, Cisplatin), diabetes or alcoholism
  • In the exome project: patients whose CMT type is already confirmed by a gene test
  • People who do not want to take part or do not sign the consent form

The registry criteria, word for word

Show all 9 criteriaShow less

Who can take part

  • Patients:; o Must have demonstrated neuropathy on nerve conduction studies or a clinically diagnosed hereditary neuropathy, in the opinion of the site investigator
  • Controls:; Must be a family member of a CMT patient who is enrolled in the 6602; AND one of the following:; Does not have a peripheral neuropathy, in the opinion of the site investigator; OR is suspected to have a peripheral neuropathy, but has not been examined at an INC site; CMT1A Modifier Study
  • Patient has a documented PMP22 duplication; AND/OR
  • Patient has a first or second degree relative (parent, child, sibling, half-sibling, aunt, uncle, grandparent, grandchild, niece, or nephew) with a documented PMP22 duplication AND a clear link between that family member and the affected patient AND a phenotype consistent with CMT1A
  • A clear link is necessary for a second-degree relative. For example, if a grandparent is affected and has a PMP22 duplication, and the parent does not have any signs, symptoms, or electrophysiology consistent with CMT1A, there is no clear link
  • In cases where clear links are not available, genetic testing is required for the patient or the first degree family member who is not clearly affected

Who cannot take part

  • All Patients: Must not have known neuropathy from a non-genetic source, such as chemotherapies (i.e., Vincristine, Taxol, Cisplatin), diabetes, alcoholism
  • CMT Exome Project Patients ONLY: Must not have a genetically confirmed form of CMT
  • All Participants: Does not wish to participate or does not sign a consent form

Where in United States

Also in 5 other countries, 6 sites

  • University of MichiganAnn Arbor, United StatesContact: Angela StovallTaking people
  • University of Colorado HospitalAurora, United StatesContact: Study RecruiterTaking people
  • Johns Hopkins UniversityBaltimore, United StatesContact: Simone ThomasTaking people
  • Harvard (Massachusetts General Hospital)Boston, United StatesContact: Lauren PoliticaTaking people
  • University of North CarolinaChapel Hill, United StatesContact: Caroline SummerourTaking people
  • Nationwide Children's HospitalColumbus, United StatesContact: Stephanie DavisTaking people
  • Connecticut Children's Medical CenterHartford, United StatesContact: Jennifer Twatchtman-BassettTaking people
  • Houston Methodist HospitalHouston, United StatesContact: Samia SaadTaking people
  • University of IowaIowa City, United StatesContact: Tiffany Grider, MS, CGCTaking people
  • Cedars-Sinai Medical CenterLos Angeles, United StatesContact: Marcela Arenas SanchezTaking people
  • University of MinnesotaMaple Grove, United StatesContact: Mia FreibergTaking people
  • St. Jude Children's Research HospitalMemphis, United StatesContact: Colin QuillivanTaking people
  • University of MiamiMiami, United StatesContact: Liuba AlonsoTaking people
  • Stanford UniversityPalo Alto, United StatesContact: Michelle JepsenTaking people
  • Children's Hospital of PhiladelphiaPhiladelphia, United StatesContact: Sabrina Yum, MDTaking people
  • University of PennsylvaniaPhiladelphia, United StatesContact: Daya StevensTaking people
  • University of RochesterRochester, United StatesContact: Janet SowdenTaking people
  • Seattle Children's HospitalSeattle, United StatesContact: Shawna FeelyTaking people

About the trial

What the trial wants to find out

This project includes two projects. One is looking for new genes that cause Charcot Marie Tooth disease (CMT). The other is looking for genes that do not cause CMT, but may modify the symptoms a person has.

The 2 groups in the trial

  • CMT1A

    Families/people with genetically defined CMT1A

  • Genetically undefined CMT

    Families/people with genetically undefined CMT with common causes ruled out.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Genetics of Charcot Marie Tooth Disease (CMT) - Modifiers of CMT1A, New Causes of CMT
Plain-language title
Searching for genes behind Charcot-Marie-Tooth disease and its symptom differencesGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
27 October 2026